3 Active Ingredients Leader, Respiratory Medicines and Global Generics Stocks With a Strong Future Roadmap: Divi's Laboratories, Cipla and Lupin

Respiratory, API and global generic stocks let investors follow companies that supply ingredients and medicines to patients around the world. Divi's Laboratories, Cipla and Lupin cover a leading active ingredients maker, respiratory medicines and a global generics and specialty franchise.

This list covers three respiratory, API and global generic stocks with complete current figures: Divi's Laboratories, Cipla and Lupin. Every figure comes from the latest reported financials and the 21 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Respiratory, API and Global Generic Stocks?

Respiratory, API and global generic stocks are listed pharmaceutical companies that make active ingredients, inhalers and generic medicines for India and regulated markets. Their earnings depend on approvals, launches and plant capacity.

Respiratory, API and Global Generic Stocks at a Glance

On valuation, Cipla and Lupin trade at a P/E below the industry P/E, while Divi's Laboratories trades above it, which reflects the growth the market already expects. Readers comparing respiratory, API and global generic stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in respiratory, API and global generic stocks can use the coming numbers to test whether growth is holding.

Why Do Respiratory, API and Global Generic Stocks Have a Strong Roadmap in India?

Respiratory, API and global generic stocks have a strong roadmap in India because global buyers keep sourcing quality ingredients and medicines from Indian plants while chronic care demand rises at home.

• Ingredient demand. Global drug makers rely on Indian suppliers for active ingredients.
• Respiratory care. Inhalers and related therapies see steady demand.
• Complex generics. Harder-to-make products earn better pricing.

Why Divi's Laboratories Features Among These Respiratory, API and Global Generic Stocks

Among the respiratory, API and global generic stocks on this list, Divi's Laboratories is a Hyderabad-based maker of active pharmaceutical ingredients, intermediates and custom synthesis products, serving large global pharma companies from large-scale manufacturing sites.

Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%. Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%.

In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore. The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P/E of 82.5, above the industry P/E of 36.0.

Roadmap: The company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.

What to watch: Check the order flow in custom synthesis and the commissioning of new capacity.

Why Cipla Features Among These Respiratory, API and Global Generic Stocks

Among the active ingredient leader shares on this list, Cipla is a Mumbai-based pharmaceutical company with strengths in respiratory medicines, anti-infectives and chronic therapies. It sells branded and generic products in India, South Africa, the United States and other markets.

In the June 2026 quarter, revenue grew 1.6% year on year to Rs 7,330 crore. Revenue rose from Rs 22,044 crore in FY22 to Rs 29,045 crore in FY26, a compound annual growth rate of 7.1%.

Net profit grew from Rs 2,559 crore in FY22 to Rs 3,870 crore in FY26, which works out to a compound annual growth rate of 10.9%. The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 107,528 crore. The stock trades at a P/E of 32.0, below the industry P/E of 36.0.

Roadmap: The company is deepening its position in respiratory and complex generic products while expanding its consumer health and domestic prescription brands. A wide global footprint spreads its earnings across several markets.

What to watch: Follow new product launches in the United States and the growth of key domestic brands.

Why Lupin Features Among These Respiratory, API and Global Generic Stocks

Among the three companies on this list, Lupin is a Mumbai-headquartered global pharmaceutical company with a presence in branded generics in India, complex generics and specialty products in the United States, and active ingredients, with strength in respiratory, cardiovascular, anti-diabetic and anti-infective therapies.

The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0.

Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore.

Roadmap: The company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.

What to watch: Track key launches in the United States, especially in inhalation and complex injectables, and the growth of the India branded business.

Divi's Laboratories vs Cipla vs Lupin on Key Financials

The table below sets the three respiratory, API and global generic stocks side by side on revenue, profit and margin, using reported figures.

Lupin posts the highest return on equity in this group at 23.8%. Cipla has the largest FY26 revenue at Rs 29,045 crore, and Lupin shows the fastest revenue growth with a 15.0% compound annual rate. A useful habit with respiratory, API and global generic stocks is to check each new quarterly result against the capacity plans the company described earlier.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Respiratory, API and Global Generic Stocks

Every theme carries risks that deserve a check before any decision. For these respiratory, API and global generic stocks, the main points are: Long-term active ingredient leader shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Pricing pressure. Competition can lower the prices of widely available generics.
• Regulatory inspections. Plants must keep meeting the standards of global regulators.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter respiratory, API and global generic stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Respiratory, API and Global Generic Stocks

Respiratory, API and global generic stocks reward investors who follow approvals, launches and plant utilisation together. Divi's Laboratories, Cipla and Lupin each pair scale with strong science. Based on the 21 October 2026 close, Divi's Laboratories trades at Rs 9,190, Cipla at Rs 1,314 and Lupin at Rs 1,964. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these respiratory, API and global generic stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track respiratory, API and global generic stocks, set price alerts and get research-backed stock ideas.

What are respiratory, API and global generic stocks?

Ans. Respiratory, API and global generic stocks are listed pharmaceutical companies that make active ingredients, inhalers and generic medicines for India and regulated markets. Their earnings depend on approvals, launches and plant capacity. This list looks at three of them, Divi's Laboratories, Cipla and Lupin, using reported FY22 to FY26 financials and the 21 October 2026 closing prices.

Which respiratory, API and global generic stocks are covered in this list?

Ans. This list covers Divi's Laboratories, Cipla and Lupin. Based on the 21 October 2026 close, Divi's Laboratories traded at Rs 9,190, Cipla at Rs 1,314 and Lupin at Rs 1,964. Their return on equity ranges from 11.3% to 23.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.1% to 15.0%.

Why do respiratory, API and global generic stocks have a strong future roadmap in India?

Ans. Respiratory, API and global generic stocks have a strong roadmap in India because global buyers keep sourcing quality ingredients and medicines from Indian plants while chronic care demand rises at home. The main drivers are as follows. Ingredient demand. Global drug makers rely on Indian suppliers for active ingredients. Respiratory care. Inhalers and related therapies see steady demand. Complex generics. Harder-to-make products earn better pricing. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Divi's Laboratories performed financially?

Ans. Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%. Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%. In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore. The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P/E of 82.5, above the industry P/E of 36.0. Looking ahead, the company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.

How has Cipla performed financially?

Ans. Revenue rose from Rs 22,044 crore in FY22 to Rs 29,045 crore in FY26, a compound annual growth rate of 7.1%. Net profit grew from Rs 2,559 crore in FY22 to Rs 3,870 crore in FY26, which works out to a compound annual growth rate of 10.9%. In the June 2026 quarter, revenue grew 1.6% year on year to Rs 7,330 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 107,528 crore. The stock trades at a P/E of 32.0, below the industry P/E of 36.0. Looking ahead, the company is deepening its position in respiratory and complex generic products while expanding its consumer health and domestic prescription brands. A wide global footprint spreads its earnings across several markets.

How has Lupin performed financially?

Ans. Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore. The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0. Looking ahead, the company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.

What risks should investors check before buying respiratory, API and global generic stocks?

Ans. Investors should check a few risks before buying respiratory, API and global generic stocks. Pricing pressure. Competition can lower the prices of widely available generics. Regulatory inspections. Plants must keep meeting the standards of global regulators. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of respiratory, API and global generic stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 21 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.